Effects of a Community Pharmacist-Based Diabetes Patient-Management Program on Intermediate Clinical Outcome Measures
|
|
- Clarence McCarthy
- 6 years ago
- Views:
Transcription
1 RESEARCH Effects of a Community Pharmacist-Based Diabetes Patient-Management Program on Intermediate Clinical Outcome Measures OBJECTIVES: Evaluate a community pharmacist-based diabetes patient-management program by examining the pharmacists impact on five intermediate outcomes: glycosolated hemoglobin (HbA1c), blood pressure, body mass index, lipid levels, and medication use in patients with diabetes. SETTING: A network of community pharmacies in West Virginia and southeastern Ohio. PATIENTS: The program was available to all patients with diabetes who attended the network pharmacies regardless of baseline glycemic control. Of the 47 patients initially enrolled, 32 stayed in the program for at least 6 months during the year-long study (median time in program was 9 months). INTERVENTION: Pharmacists provided a basic, standardized diabetes education program during three 1-hour sessions. This was accompanied by a clinical assessment and a report to the patient s primary care physician. The patients met with the pharmacist every 3 months for continued monitoring. After each visit, the patient s primary care physician was sent a report along with recommendations for drug therapy modification when appropriate. MAIN OUTCOME MEASURES: HbA1c, blood pressure, total cholesterol, lowdensity lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides, body mass index, and the number of drug therapy modifications. RESULTS: There was significant improvement in total cholesterol (t= 2.58, p=0.015) and LDL (t= 2.56, p=0.017) for the 32 participating patients. HbA1c, BMI, blood pressure, HDL and triglycerides did not change significantly across all patients. For a subgroup of 10 patients with baseline HbA1c>8%, average HbA1c declined significantly from 9.8% to 8.6% (t= 3.00, p=0.015). During the study, the 32 patients had a total of 53 modifications to their medication regimens. The most common was a change in dose of oral diabetes medications. CONCLUSIONS: The pharmacist-based diabetes patient-management program was associated with improvements in total cholesterol and LDL across all patients who maintained enrollment in the program for at least 6 months. Improvements in HbA1c were also demonstrated for a subgroup of patients who had poor glycemic control at baseline. KEYWORDS: Diabetes, Disease Management, Pharmaceutical Care J Managed Care Pharm 2001: DAVID P. NAU, R.PH., PH.D.,* is Assistant Professor, College of Pharmacy, University of Michigan, Ann Arbor, Michigan; CHARLES D. PONTE, PHARM.D., CDE, BCPS, FASHP, FCCP, FAPHA, is Professor, Departments of Clinical Pharmacy and Family Medicine, West Virginia University, Morgantown, West Virginia ADDRESS CORRESPONDENCE: David Nau, College of Pharmacy, University of Michigan, 428 Church St., Ann Arbor, MI, ; Tel: (734) ; Fax: (734) ; dnau@umich.edu * At the time of this study, Dr. Nau was an Assistant Professor, West Virginia University School of Pharmacy. This study was funded in part by The Health Plan of the Upper Ohio Valley, The National Community Pharmacists Association Foundation, Hoerchst-Marion Roussel (now Aventis), and Bristol-Myers Squibb. The authors thank Joshua Blevins for assistance with data collection and the pharmacists of OVPCN who participated in this project (John Bernabei, Roger Cole, Aldo Cristante, Bob Gelner, Mike Kacsmar, Joe Jefferies, and Adele Storm). Copyright 2002 Academy of Managed Care Pharmacy, Inc. All rights reserved. by David P. Nau and Charles D. Ponte Disease management programs for diabetes have become increasingly common. This is likely due to the high costs of diabetes complications, which lead to health plans spending up to four times as much on the care of persons with diabetes compared to the general population. 1 Many of these higher costs are associated with the management of the complications of diabetes, such as myocardial infarction (MI) which is estimated to cost $27,630 per event or end-stage renal disease (ESRD) which is estimated to cost $53,659 per year. 2,3 However, the American Diabetes Association (ADA) estimates that the complications of diabetes could be reduced dramatically if patients maintained adequate control of their diabetes. Results from the Diabetes Control and Complications Trial (DCCT) suggest that intensive treatment and monitoring for persons with Type 1 diabetes could lead to substantial reductions in the risk of retinopathy, nephropathy, neuropathy, dyslipidemia, and cardiovascular disease. 4 Likewise, the United Kingdom Prospective Diabetes Study (UKPDS) found that intensive glycemic control of persons with Type 2 diabetes can reduce the overall rate of microvascular complications by approximately 25%. However, the rate of macrovascular complications (e.g., fatal and nonfatal myocardial infarction and sudden death) was not significantly affected by tight glycemic control. 5 Unfortunately, many persons with diabetes fail to receive education about diabetes and many do not receive or selfadminister the recommended frequency of tests to monitor their disease. 6,7,8 The National Committee for Quality Assurance (NCQA) HEDIS (Healthcare Employer Data and Information Set) indicators for diabetes were expanded in The new Comprehensive Diabetes Care indicator set estimates the percentage of health plan members, 18 to 75 years old, with Type 1 and Type 2 diabetes who during the measurement year: (1) received a glycosylated hemoglobin (HbA1c) test; (2) had poorly controlled HbA1c (HbA1c >9.5%); (3) received a cholesterol (LDL-c) test; (4) had an LDL-c level less than 130mg/dl; (5) received a microalbumin test; or (6) received a dilated eye exam. 9 As a result, many managed care organizations have increased their focus on the quality of care for members with diabetes and have 48 Journal of Managed Care Pharmacy JMCP January/February 2002 Vol. 8, No. 1
2 developed disease management programs that rely heavily on non-physician providers of care. Several studies have shown that disease management services are effective in improving the quality of care for persons with diabetes. 10,11,12 An increasing number of disease management programs utilize pharmacists to assist in the monitoring and management of patients with diabetes. The VA Medical Center in Pittsburgh found that persons with Type 2 diabetes who were enrolled in its pharmacist-based program experienced significant improvements in glycemic control within 6 months. 13 After adjusting for the costs of the program, it was estimated that the net savings to the VA Medical Center for 15 of the most severely ill patients was more than $103,000 per year. In 1997, Fincham and Lofholm evaluated community pharmacists diabetes-related interventions and estimated the one-time cost-savings from the prevention of hospitalizations or unnecessary office visits were $4,295 per patient. 14 A network of community pharmacists saved the city of Asheville, North Carolina, more than $900 per patient per year on diabetes care, while several other authors have reported the positive impact of pharmacist-based services on glycemic control Nonetheless, managed care organizations have not yet fully utilized community pharmacists to improve the quality of diabetes care. Diabetes Care Network FIGURE 1 The Ohio Valley Pharmacist Care Network (OVPCN) is a group of independent community pharmacists located in the northern panhandle of West Virginia and southeastern Ohio. This network was formed in 1998 with the goal of establishing common pharmaceutical care programs that would meet the needs of patients, physicians, and payers in the region. At the time of this publication, the membership of OVPCN consisted of 13 pharmacists at seven pharmacies. Additional details on the network are available in the July/August 2001 issue of JMCP. 19 A consultant from the West Virginia University School of Pharmacy assisted the pharmacists in developing standardized diabetes care services at the network pharmacies. The goals of the program are based on the American Diabetes Association Standards of Medical Care for Patients with Diabetes Mellitus. 20 All network pharmacists completed a series of training programs in diabetes care prior to program implementation. The training included certificate programs in diabetes care (either the program offered jointly by the American Pharmaceutical Association and American Association of Diabetes Educators or the home-study program offered by the National Institute for Pharmaceutical Care Outcomes) and a two-day training program offered by West Virginia University. Additionally, the pharmacists received training in the operation of equipment and devices to be used in the diabetes care program. OVPCN established a tentative agreement with a local managed care organization (MCO) to assess and improve the quality of diabetes care for the MCO s enrollees. The agreement specified the conduct of a pilot study prior to consideration of expansion of the clinical intervention program to all diabetic patients. The MCO is an IPA-HMO with just over 100,000 covered lives in southeastern Ohio and northern West Virginia. Objective The objective of this pilot study was to determine whether the diabetes patient-management program provided through the OVPCN was an effective means of improving clinical outcomes in persons with Type 2 diabetes. Methods Components of Education Program for Patients Session 1 Overview: The pharmacist gave a basic overview of the causes and complications of diabetes, goals of diabetes control, measuring outcomes of diabetes management, and symptoms and treatment of hypoglycemia. Blood Glucose Monitoring: This section reviewed the importance of blood glucose monitoring, how to use a blood glucose meter, when to check blood glucose, and target levels. Session 2 Insulin: The pharmacist reviewed how insulin works in the body; for patients using insulin, the pharmacist explained how to use, store, mix, and inject insulin, and discussed dosing schedules and adjustments. Oral Medications for Diabetes: This session covered the different options to treat diabetes with oral medication. The pharmacist reviewed how they work, their potential side effects and drug interactions, and how to take them correctly. Session 3 Ongoing Monitoring of Diabetes: The pharmacist discussed monitoring of blood glucose, blood pressure, and hemoglobin A1c, urine testing, and lipids. Avoiding Long-Term Complications: This section describe lifestyle modifications and reviewed the body systems that can be damaged by diabetes. Design This pilot study used a single-group, retrospective, non-experimental, pre/post design to assess change in selected clinical measures in a small group of Type 2 diabetic patients. Since the service was only available to patients at a limited number of pharmacies, only a small proportion of the total persons with diabetes in the HMO were able to use the service. Data were collected as part of the ongoing diabetes care program. Thus, data included in this study came from the baseline assessment and from follow-up visits that occurred every 3 months. Subjects data were not included in the final analyses if Vol. 8, No. 1 January/February 2002 JMCP Journal of Managed Care Pharmacy 49
3 they did not return for follow-up visits at least once in the 6 months after enrollment. Additional details on the baseline data from this project are published in the July/August 2001 JMCP. 19 Subjects At the request of the HMO, all patients diagnosed with Type 2 diabetes were eligible to receive the pharmacists services. Each of the network pharmacists solicited the involvement of current patients and also accepted referrals from physicians (although physician referral was not required in order for the pharmacists to obtain compensation). None of the patients were newly diagnosed at the time of enrollment. No payment was required of patients who participated in this program. Patient-Management Services Standardized diabetes patient-management services were established at the network pharmacies to ensure consistency of care. The services were provided through scheduled appointments in the pharmacy and consisted of a baseline assessment and education program, as well as follow-up visits with patients to evaluate their progress toward the clinical goals. The goals of the program were based on the ADA Standards for Medical Care for persons with diabetes and are summarized in a prior description of the OVPCN services. 20 The educational program was conducted through three individual face-to-face discussions between pharmacist and patient in the pharmacist s office. Each educational session lasted approximately 60 minutes. The basic components of the educational program were standardized, although the pharmacist tailored the material to the patient s drug therapy and existing knowledge of diabetes. A desktop flip-chart with color graphics was used to guide the patient through the basics of diabetes management and also enhanced consistency between the participating pharmacists. The key components of the diabetes education program are presented in Figure 1 (page 49). The pharmacists also collected data that helped to identify drug-related problems and the need for therapy modification. These data included HbA1c, blood pressure, lipid profile, and BMI (estimated from weight and height). The pharmacists also determined whether the patient s care conformed to the HMO s therapeutic guidelines for primary care physician visits, eye/foot exams, immunizations, and smoking cessation or dietician referrals. All data were provided to the patient s primary care physician. The primary care physician was also contacted to discuss the patient s need for therapy modification or referrals. The patient s progress towards the ADA-recommended therapeutic goals was tracked by the pharmacist via follow-up appointments scheduled approximately 3 months apart. These data were also provided to the patients and their physicians. Thus there were three components to the diabetes patient-management services: (1) patient education, (2) patient monitoring, and (3) physician-pharmacist collaboration. Clinical data collection The clinical data were collected and recorded by the pharmacists as part of the standard care program. Additional detail on the data collection methods can be found in the July/August 2001 issue of JMCP. 19 The HbA1c levels were determined by analyzing blood samples in the Bayer DCA2000+ machine. The HbA1c reagent cartridge requires only 1 microliter of blood from a fingerstick and results are reported within 5 minutes. The lipid profile was conducted through the use of the Cholestech LDX analyzer using a fingerstick sample of blood. This test provides estimates of the total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride and glucose levels. All samples were drawn from patients in a fasting state. The analyses conducted with the Cholestech LDX and DCA2000+ are waived tests under the Clinical Laboratory Improvement Amendment (CLIA) and can be performed in the pharmacy by trained personnel. 21 The pharmacists also monitored the patient s blood pressure at each visit using a manual sphygmomanometer. Two blood pressure readings were taken with the patient in the sitting position. The mean of the two blood pressures was used for analyses. Medication changes The changes in each patient s drug therapy were determined by review of the patient s chart in the pharmacy as well as the electronic dispensing record. In many instances, the specific change arose from a conversation between the pharmacist and physician in which numerous options were discussed. Thus, there were not always explicit recommendations from the pharmacists that could be accepted or rejected by the physician. However, since all of the changes occurred subsequent to a verbal or written interaction between the pharmacist and physician, it was assumed that all changes were influenced by the pharmacist-physician interaction. Statistical analyses All data were analyzed using SPSS-PC version 7.5. To evaluate the change in clinical endpoints, a paired t-test was conducted on each variable using a significance level of p<0.05. The patients had differing lengths of time between the baseline and follow-up assessments, and some patients had multiple followup assessments. To simplify the analyses, data from the last follow-up visit during the year-long study were used for comparisons with baseline. Results Subjects Although 47 patients were initially enrolled in the study, only 32 maintained participation in the program for at least 6 months. There were no significant differences in baseline characteristics 50 Journal of Managed Care Pharmacy JMCP January/February 2002 Vol. 8, No. 1
4 between the patients who continued and those who did not. All subsequent analyses are based on the 32 participants who maintained enrollment for at least 6 months (Table 1, this page). Clinical Measures A summary of the clinical measures is presented in Table 2 (this page). The mean baseline HbA1c for the 32 participants was 7.4%, which is indicative of relatively good control. However, 10 of the 32 participants had an HbA1c over 8% at baseline, while 23 had an LDL greater than 100mg/dl and 22 had a BMI greater than 30kg/m 2. The mean scores on all measures moved in the desired direction with statistically significant improvements found in total cholesterol (t= 2.58, p=0.015) and LDL (t= 2.56, p=0.017). Blood pressure, HDL, triglycerides, BMI, and HbA1c did not change significantly across all 32 patients. For the 10 patients with baseline HbA1c >8%, the average HbA1c declined significantly, from 9.8% to 8.6% (t= 3.00, p=0.015). Medication Use The 32 participants experienced 53 medication changes during the study period (Table 3, this page). Twenty-seven (51%) of the changes involved a modification of oral diabetes medications. One patient was started on insulin while one patient had an adjustment in insulin dose. Drug therapy for dyslipidemia was initiated in five patients and was modified in seven patients. Antihypertensive medications were started in two patients and adjusted in 10 patients. Discussion This report provides some support for a positive impact of specially-trained community pharmacists in the care of persons with diabetes. However, the study also highlights the difficulties of conducting a program evaluation in real-world settings. The OVPCN services were created to provide additional education and monitoring for persons with diabetes in collaboration with physicians. The collaborating HMO supported the idea of opening the services to any of its members with Type 2 diabetes without the need for a physician referral. This led to enrollment in the services by patients with quite disparate levels of glycemic control. The HMO sought to determine whether patients with diabetes could benefit from the services even if their baseline glycemic control was within an acceptable range (i.e., HbA1c <8%). It appears that the OVPCN services were beneficial to the population of patients who enrolled. Although the mean HbA1c across all 32 participants did not improve significantly, the subset of patients with an HbA1c above 8% at baseline did achieve significant improvement in glycemic control. The average reduction in HbA1c by 1.2% should lead to significant reduction in the risk of diabetes complications for these patients. 4, 5 The most common drug-therapy changes during the study were TABLE 1 Age (mean ± sd.) Demographics (n=32) 58.7 ± 11.5 years Gender Female 17 (53.1%) Male 15 (46.9%) HbA1c (baseline) Level Patients 6% % % 11 > 8% 10 TABLE 2 Baseline Follow-up Mean SD Mean SD HbA1c (%) Systolic BP (mmhg) Diastolic BP (mmhg) Cholesterol (mg/dl) a LDL (mg/dl) b HDL (mg/dl) Triglycerides (mg/dl) BMI (kg/m 2 ) SD = standard deviation, BP = blood pressure, LDL = low-density lipoproteins, HDL = high-density lipoproteins a. Significant improvement (t= 2.58, p=0.015) b. Significant improvement (t= 2.56, p=0.017) TABLE 3 Clinical Measures: Mean Scores and Standard Deviation (n=32) Medication Changes Oral Antidiabetic Change drug Change dose Add second drug Insulin Change dose Initiate insulin Antilipidemic Change drug Change dose Initiate drug Antihypertensive Change drug Change dose Initiate drug Total Vol. 8, No. 1 January/February 2002 JMCP Journal of Managed Care Pharmacy 51
5 an increase in dose of an existing antidiabetic agent or the addition of a second antidiabetic drug. Most of these changes occurred in the patients who had the worst glycemic control at baseline. Another important finding was that many patients had uncontrolled dyslipidemia. In our previous report on the OVPCN program, we identified that elevated LDL was a more common problem than poor glycemic control in the patients who participated in a baseline assessment. 19 Subsequent to the pharmacist-conducted lipid profile and the pharmacists dialogue with the patients physicians, five patients were initiated on therapy for dyslipidemia and seven other patients received dosage increases. The longitudinal data presented in this report show that both total cholesterol and LDL improved significantly across all patients in the program. This should lead to a significant reduction in the risk of cardiovascular events, which are a major cause of death among people with Type 2 diabetes. 22 Consequently, it appears that many patients with diabetes may still benefit from pharmacist-based diabetes management programs even if they have acceptable glycemic control prior to enrollment. An additional concern in adults with diabetes is blood pressure control. The mean blood pressure of patients enrolled in the patient-management program was fairly good at baseline (systolic=136.4mmhg; diastolic=82.2mmhg) and did not change significantly across all 32 patients. Nonetheless, the pharmacists worked with the patients physicians to initiate antihypertensive therapy in two patients and change therapy in 10 patients. Five of the changes in antihypertensive therapy involved the switch from a diuretic to an angiotensinogen-converting enzyme (ACE) inhibitor (or ACE/diuretic combination product) in patients whose hypertension was relatively well controlled. Although the patients who had this therapy change did not experience substantial changes in blood pressure control, they received greater renal protection through the use of the ACE inhibitor. Many drug therapy changes were made for the patients enrolled in the diabetes care program. Although most of the therapy modifications occurred after the physician and pharmacist communicated about the patient s progress, it is difficult to assess how many of the changes in drug therapy may have occurred without the pharmacist s monitoring. In some situations, the pharmacist made explicit recommendations for change. Other times, the pharmacist notified the physician that the patient was not reaching goal and the physician independently selected a course of action. Regardless of whether or not the pharmacist made explicit recommendations for drug therapy modification, we believe the monitoring report from the pharmacist and the subsequent pharmacist-physician dialogue increased the likelihood of action by the physician. The loss of patients at follow-up also points out the difficulties encountered by all practitioners who strive to provide ongoing care to patients with chronic diseases. Telephone calls to the patients who dropped out prior to their 6-month follow-up revealed a myriad of reasons for not returning. The most common reasons cited by patients for not keeping appointments were impairments to their mobility and a lack of perceived need for continued monitoring. Several more patients expressed interest in maintaining participation in the program but continually failed to keep appointments. The ideal design to evaluate the impact of pharmaceutical care for diabetes would be a prospective, randomized, controlled trial in a large number of pharmacies. Without a control group, it is difficult to assess whether the pharmacists services were truly the cause of clinical improvement. Retrospective selection of a truly comparable control group is challenging in practice-based research. A review of claims data for this HMO revealed that fewer than 10% of patients with diabetes had claims for both HbA1c and lipid profiles spaced approximately one year apart during the study period. Thus, it is unclear whether control group patients selected from this very small subset would be truly representative of the HMO s diabetic population. Additionally, clinical data (e.g., HbA1c, LDL, BP) for potential control group patients in this IPA-model HMO are only available through the patients charts kept in the physicians offices. Therefore, data collection for the formation of a control group is also challenging. It is also difficult for a community pharmacy to enroll large numbers of patients with a single disease and to maintain all of those patients in the service for an extended period of time. Many of the best-known pharmaceutical care projects for diabetes (e.g., projects in North Carolina, New Jersey, and Iowa) have maintained enrollment of fewer than 50 patients during the initial study period. It is also difficult to involve large numbers of pharmacies in such studies due to the high degree of additional training and support required by the pharmacies. Although several small studies have documented the positive impact of pharmaceutical care on diabetes patient outcomes, there is a need for larger, longer, more controlled studies of pharmaceutical care for patients with diabetes Conclusion Community pharmacists who have completed additional training in diabetes care can have a beneficial impact on the care of patients with Type 2 diabetes. Pharmacist-based patient-management services not only help to improve glycemic control in adults with HbA1c >8% but can also identify patients with uncontrolled hypertension and dyslipidemia and produce reductions in total cholesterol and LDL. Therefore, pharmaceutical care may be beneficial for all patients with diabetes regardless of baseline glycemic control. Disclosures David Nau is the principal author of this paper. Study concept and design, 52 Journal of Managed Care Pharmacy JMCP January/February 2002 Vol. 8, No. 1
6 drafting of the manuscript and statistical expertise was provided by Nau. Nau and Ponte collaborated on analysis and interpretation of data and critical revision of the manuscript. Joshua Blevins, while employed by West Virginia University, assisted with data collection. The following pharmacists of OVPCN participated in this project: John Bernabei, Roger Cole, Aldo Cristante, Bob Gelner, Mike Kacsmar, Joe Jefferies, and Adele Storm. Funding was obtained by Nau. Funding and support for this study was contributed by The HealthPlan of the Upper Ohio Valley, Aventis, Bristol- Myers Squibb, and the National Community Pharmacists Association Foundation. Administrative and technical support was provided by Steve Neal, Shelly Rouse and Kathy Parsons, all employees of The HealthPlan. References 1. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in Diabetes Care 1998; 21: American Diabetes Association. Position statement: Diabetic nephropathy. Diabetes Care 1997; 20: S24-S O Brien JA, et al. Direct medical costs of complications resulting from Type 2 diabetes in the U.S. Diabetes Care 1998; 21: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: Coonrod BA, Harris MI, Betschart J. Frequency and determinants of diabetes patient education among adults in the U.S. Population. Diabetes Care 1994; 17: Peters AL, Ossorio RC, Legorreta AP, Davidson MB. Quality of outpatient care provided to diabetic patients. Diabetes Care 1996; 19: Asch SM, et al. Measuring underuse of necessary care among elderly Medicare beneficiaries using inpatient and outpatient claims. JAMA 2000; 284; National Committee for Quality Assurance. The State of Managed Care Quality, Rubin RJ, Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. J Clin Endocrinol Metab 1998; 83: Sikka R, et al. Renal assessment practices and the effect of nurse case management of health maintenance organization patients with diabetes. Diabetes Care 1999; 22: Piette JD, et al. Use of automated telephone disease management calls in an ethnically diverse sample of low-income patients with diabetes. Diabetes Care 1999; 22: Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with Type 2 diabetes by pharmacists in primary care clinics. Annals Pharmacother 1998; 32: Fincham JE, Lofholm PW. Saving money and lives pharmacist care for diabetes patients. America s Pharmacist 1998; (March): The Asheville project. Pharmacy Times 1998 (October supplement). 16. Berringer R, et al. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc 1999; 39: Baran RW, et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health-Syst Pharm 1999; 56: Kelly C, Rodgers PT. Implementation and evaluation of a pharmacist-managed diabetes service. J Managed Care Pharm 2000; 6: Nau DP, Blevins JD, Neal SE. Collaborating with community pharmacists to improve the quality of diabetes care in an IPA-model HMO. J Managed Care Pharm 2001; 7: American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000; 23: S32-S Rosenthal WM. Establishing a pharmacy-based laboratory service. J Am Pharm Assoc. 2000; 40: American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2000; S57-S60. Vol. 8, No. 1 January/February 2002 JMCP Journal of Managed Care Pharmacy 53
Evaluating the Impact of a Pharmacist-Care Program for Persons with Diabetes
Evaluating the Impact of a Pharmacist-Care Program for Persons with Diabetes Prepared for: National Community Pharmacists Association Foundation by: David Nau, R.Ph., Ph.D. Assistant Professor Josh Blevins
More informationClinical and Economic Summary Report. for Employers
Clinical and Economic Summary Report for Employers Magaly Rodriguez de Bittner, PharmD, CDE, FAPhA Director, P 3 Program Dawn Shojai, PharmD Assistant Director, P 3 Program P 3 Clinical & Economic Summary
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More informationEvaluating Medication Use for Continuous Quality Improvement in Diabetes Care
CONTEMPORARY SUBJECT Evaluating Medication Use for Continuous Quality Improvement in Diabetes Care DAVID P. NAU, PhD Continuous quality improvement (CQI) is the structured organizational process for involving
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationGlycemic Control in Pharmacist-Managed Insulin Titration Versus Standard Care in an Indigent Population
Glycemic Control in Pharmacist-Managed Insulin Titration Versus Standard Care in an Indigent Population Jamie M. Pitlick, PharmD, BCPS, and Amie D. Brooks, PharmD, BCPS Address correspondence to Jamie
More informationKey Elements in Managing Diabetes
Key Elements in Managing Diabetes Presentor Disclosure No conflicts of interest to disclose Presented by Susan Cotey, RN, CDE Lennon Diabetes Center Stephanie Tubbs Jones Health Center Cleveland Clinic
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationTable of Contents. Page 2 of 20
Page 1 of 20 Table of Contents Table of Contents... 2 NMHCTOD Participants... 3 Introduction... 4 Methodology... 5 Types of Data Available... 5 Diabetes in New Mexico... 7 HEDIS Quality Indicators for
More informationStudent Paper PRACTICE-BASED RESEARCH
The Role of Clinical Pharmacists in Modifying Cardiovascular Disease Risk Factors Autumn Bagwell, PharmD. 1 ; Jessica W. Skelley, PharmD 2 ; Lana Saad, PharmD 3 ; Thomas Woolley, PhD 4 ; and DeeAnn Dugan,
More informationCHI Franciscan. Matt Levi Director Virtual Health Services. March 31, 2015
CHI Franciscan Matt Levi Director Virtual Health Services March 31, 2015 Reflection / 2 Agenda Introduction and background Matt Levi Director of Franciscan Health System Virtual Health Katie Farrell Manager
More informationDiabetes affects 25.8 million people in the United
Impact of Clinical Pharmacy Services on Outcomes and Costs for Indigent Patients With Diabetes Marissa Escobar Quinones, PharmD, CDE; Margaret Youngmi Pio, PharmD, BCPS, CDE; Diem Hong Chow, PharmD, CDE;
More informationDiabetes affects 29.1 million
Evaluation of Diabetes Education and Pharmacist Interventions in a Rural, Primary Care Setting Lisa T. Meade, 1,2 Rebecca C. Tart, 2 and Hillary L. Buzby 3 1 Wingate University, Hickory, NC 2 Catawba Valley
More informationHow to Conduct an Effective Medication Therapy Management Session in the Community Pharmacy
How to Conduct an Effective Medication Therapy Management Session in the Community Pharmacy Presented by: Dale Christensen, University of North Carolina Susmita Chavala, Humana Ed Staffa, Community MTM
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationTo reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.
E Nancy A. Haller, MPH, CHES, Manager, State Wellness Program M PLOYEES To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees. To suspend or decrease the rising costs
More information2017 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members
2017 Diabetes Program Evaluation Our mission is to improve the health and quality of life of our members Diabetes Program Evaluation Program Title: Diabetes Program Evaluation Period: January 1, 2017 December
More informationClinical Practice Guideline Key Points
Clinical Practice Guideline Key Points Clinical Practice Guideline 2008 Key Points Diabetes Mellitus Provided by: Highmark Endocrinology Clinical Quality Improvement Committee In accordance with Highmark
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationDiabetes Quality Improvement Initiative
Diabetes Quality Improvement Initiative Community Care of North Carolina 2300 Rexwoods Drive, Ste. 100 Raleigh, NC 27607 (919) 745-2350 www.communitycarenc.org 2007 Background The Clinical Directors of
More informationAn estimated 20.8 million Americans 7% of the population
Provider Organization Performance Assessment Utilizing Diabetes Physician Recognition Program Bruce Wall, MD, MMM; Evelyn Chiao, PharmD; Craig A. Plauschinat, PharmD, MPH; Paul A. Miner, PharmD; James
More informationClinical Therapeutics/Volume 33, Number 1, 2011
Clinical Therapeutics/Volume 33, Number 1, 2011 Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes: An Analysis of Data From Electronic Medical Records
More informationAdministrative Consultant for Endocrine Offices
Business Manager & Consultant Administrative Consultant for Endocrine Offices 703 Mt Rock Rd Carlisle, PA 17015 Tel: 717-798-4820 (Cell) CPT is a registered trademark of AMA. Endocrinology Is it: Patient
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationDiabetes Management: Interventions Engaging Community Health Workers
Diabetes Management: Interventions Engaging Community Health Workers Community Preventive Services Task Force Finding and Rationale Statement Ratified April 2017 Table of Contents Intervention Definition...
More information2/27/2017. Point of Care Testing- current and future opportunities for pharmacists in Virginia. Financial Disclosures. Pre-Assessment.
Point of Care Testing- current and future opportunities for pharmacists in Virginia Objectives Define the Pharmacy Practice Act in Virginia M AR G AR E T L AN D I S, P H AR M. D. K R O G E R P H AR M AC
More informationBob Davis, PharmD, FAPhA Professor and Chair, KPIC South Carolina Primary Health Care Association September 19, 2015
Bob Davis, PharmD, FAPhA Professor and Chair, KPIC davisb@kennedycenter.sc.edu South Carolina Primary Health Care Association September 19, 2015 Myrtle Beach, SC Kennedy Pharmacy Innovation Center Foundation
More informationFY 2018 WISEWOMAN / Wise Choices Procedure Code Reference Chart
99203 Office or other outpatient visit for the evaluation and management of a new patient, a detailed history; a detailed examination; and medical decision making of low complexity. Usually the presenting
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationRESEARCH. What is already known about this subject. What this study adds
RESEARCH Impact of a Clinical Pharmacy Program on Changes in Hemoglobin A1c, Diabetes-Related Hospitalizations, and Diabetes-Related Emergency Department Visits for Patients with Diabetes in an Underserved
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationDiabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.
Health Care Disparities: Medical Evidence Diabetes Effects 2.8 Million People in US 7% of the US Population Sixth Leading Cause of Death Kenneth J. Steier, DO, MBA, MPH, MHA, MGH Dean of Clinical Education
More informationPrimary Care Pharmacist Integration and Reimbursement Models
Primary Care Pharmacist Integration and Reimbursement Models May 20, 2015 MODERATOR: Marie Smith, PharmD Palmer Professor and Assistant Dean, Practice and Public Policy Partnerships, UConn School of Pharmacy
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More information2012 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members
2012 Diabetes Program Evaluation Our mission is to improve the health and quality of life of our members Diabetes Program Evaluation Program Title: Diabetes Program Evaluation Period: January 1, 2012 December
More informationHeather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health
Heather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health Disclosure Heather Dacus has no real or perceived vested interests that
More informationThe Global Agenda for the Prevention of Diabetes: Research Opportunities
The Global Agenda for the Prevention of Diabetes: Research Opportunities William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationPCMH 2018 Enrollment and Update August 25, 2017
PCMH 2018 Enrollment and Update August 25, 2017 Enrollment Requirements Anne Santifer HealthCare Innovations Department of Human Services 2018 Enrollment Requirements A physician practice that is enrolled
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationConsensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0
Consensus Core Set: ACO and PCMH / Primary Care s 0018 Controlling High Blood Pressure patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationDiabetes Overview. How Food is Digested
Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How
More informationPharmacy Partnership to Improve Patient Outcomes
Pharmacy Partnership to Improve Patient Outcomes Minnesota Rural Health Conference Session 2B Ryan M. Harden, MD MS Kendra Metz, Pharm D Sarah Nelson, MD June 25, 2018 Involved Partners Involved Partners
More informationMedication Therapy Management: Improving Health and Saving Money
Medication Therapy Management: Improving Health and Saving Money Ed Staffa, RPh Vice President, Pharmacy Mirixa Corporation estaffa@mirixa.com July 23, 2008 MTM At A Glance The U.S. health care system
More information8/12/2016. Outline. New CPT Code for Pre-Diabetes Education. Medicare Proposed Coverage for DPP. Medicare Proposed Coverage for DPP cont.
New CPT Code for Pre-Diabetes Education 0403T: Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals
More informationEconomics of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol
s of Reducing Out-of-Pocket Costs for Cardiovascular Preventive Services for Patients with High Blood Pressure and High Cholesterol Summary Evidence Tables Study Author (Year) Bunting (2008) Prepost Incomplete
More informationLOUISIANA MEDICAID PROGRAM ISSUED: 02/01/12 REPLACED: 02/01/94 CHAPTER 5: PROFESSIONAL SERVICES SECTION 5.1: COVERED SERVICES PAGE(S) 6
Diabetes Education Management Training Diabetes self management training (DSMT) is a collaborative process through which recipients with diabetes gain knowledge and skills needed to modify behavior and
More informationIn 2001, the National Cholesterol Education Program
At a Glance Practical Implications p 330 Author Information p 333 Full text and PDF www.ajpblive.com Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation Original Research
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationMetabolic Monitoring Point of Care Testing
Metabolic Monitoring Point of Care Testing Committee on Provider Quality 5/16/18 Revised 8/2/18 Metabolic Monitoring Goals Identify treatable pathology in a high risk population and link to medical care
More informationTools for Targeting High Risk Patients in Your Practice. Statement of Disclosure
Tools for Targeting High Risk Patients in Your Practice Joseph Vande Griend, PharmD, BCPS, CGP Assistant Professor, University of Colorado Departments of Clinical Pharmacy and Family Medicine Skaggs School
More informationChronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
More informationMary Ann Hodorowicz RDN, MBA, CDE, CEC (Certified
Mary Ann Hodorowicz RDN, MBA, CDE, CEC (Certified Endocrinology Coder) Mary Ann Hodorowicz, RDN, MBA, CDE, CEC, is a licensed registered dietitian and certified diabetes educator and earned her MBA with
More informationMoving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit
Moving to an A1C-Based Screening & Diagnosis of Diabetes By Prof.M.Assy Diabetes&Endocrinology unit is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine terminal residue. Clin
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationTable 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings
CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationProject Title Community Pharmacy Participation in Health Screening and Medication Therapy Management
Project Title Community Pharmacy Participation in Health Screening and Medication Therapy Management Author and Location Sahar M.Rashed, Ph.D, Pharm.D (srashed@utmem.edu) Associate Professor of Clinical
More informationClinical Care Performance. Financial Year 2012 to 2018
Clinical Care Performance Financial Year 2012 to 2018 SHP Clinical Care Performance Diabetes Mellitus Hyperlipidemia Hypertension Diabetes Mellitus Find out how our patients are doing for: HbA1C HbA1c
More informationDiabetes Management Quality Improvement in a Family Practice Residency Program
Diabetes Management Quality Improvement in a Family Practice Residency Program John E. Sutherland, MD, James D. Hoehns, PharmD, Brian O Donnell, PhD, and R. Todd Wiblin, MD, MS Background: Diabetes is
More informationHigh-quality diabetes care can
Development and Evolution of a Primary Care Based Diabetes Disease Management Program Robb Malone, PharmD, CDE, CPP; Betsy Bryant Shilliday, PharmD, CDE, CPP; Timothy J. Ives, PharmD, MPH; and Michael
More informationQUALITY IMPROVEMENT Section 9
Quality Improvement Program The Plan s Quality Improvement Program serves to improve the health of its members through emphasis on health maintenance, education, diagnostic testing and treatment. The Quality
More informationClinical Inertia. The Promise of Collaborative Care for Treating Behavioral Health and Chronic Medical Conditions. Study: 161,697 Patients 4/12/17
The Promise of Collaborative Care for Treating Behavioral Health and Chronic Medical Conditions Paul Ciechanowski, MD, MPH Clinical Associate Professor, University of Washington Chief Medical Officer,
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationperformance measurements. Nurses were trained as case managers and clinical auditors of diabetes care.
16 %33.6 %31.7 %20.8 100 133.2 %20.6 %7 135.3 Dubai is the second largest of the 7 Emirates of the United Arab Emirates (UAE) with almost 700 000 inhabitants. Like other Gulf countries, this Emirate is
More informationImproving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE
More informationGetting Hypertension Under Control
Getting Hypertension Under Control Learning Objectives EXPLAIN the factors involved in patient medication non-adherence. OUTLINE the results of studies focusing on medication adherence issues in patients
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationAddressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:
Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her
More informationGuiding Principles. for Diabetes Care: For Health Care. Providers
Guiding Principles N A T I O N A L for Diabetes Care: D I A B E T E S For Health Care E D U C A T I O N Providers P R O G R A M The National Diabetes Education Program (NDEP) has developed these Guiding
More informationImproving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies
Improving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies Megan Willson, PharmD, BCPS; Catrina Schwartz, PharmD, BS; Jennifer Robinson, PharmD Spokane,
More informationRISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION
2015 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 22(2):159-165 doi: 10.1515/rjdnmd-2015-0020 RISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION Mónika
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationCase Management and Care Coordination: Two Successful Models
Case Management and Care Coordination: Two Successful Models Asthma Educator Sharing Day October 17, 2011 Karen Meyerson, MSN, RN, FNP-C, AE-C Asthma Network of West Michigan Jan Roberts, RN, BSN, AE-C
More informationPresenter Disclosure Information
Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More information2015 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members
2015 Diabetes Program Evaluation Our mission is to improve the health and quality of life of our members Diabetes Care Program Evaluation Program Title: Diabetes Care Program Evaluation Period: January
More informationAchieving Quality and Value in Chronic Care Management
The Burden of Chronic Disease One of the greatest burdens on the US healthcare system is the rapidly growing rate of chronic disease. These statistics illustrate the scope of the problem: Nearly half of
More informationImpact and Value of Pharmacist Interventions in Different Settings
Impact and Value of Pharmacist Interventions in Different Settings Cheryl Pegus MD MPH Chief Medical Officer Walgreen Co. March 15, 2011 Chronic Care Management Today: The Challenge Less Effective Lower
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationPREVENTATIVE COMMUNITY PHARMACY DIABETES MANAGEMENT PROGRAMS BROOKE HUDSPETH, PHARMD, CDE, MLDE KROGER DIABETES CARE
PREVENTATIVE COMMUNITY PHARMACY DIABETES MANAGEMENT PROGRAMS BROOKE HUDSPETH, PHARMD, CDE, MLDE KROGER DIABETES CARE DISCLOSURE STATEMENT Brooke Hudspeth is employed by The Kroger Co. No other conflicts
More informationPQRS in TRAKnet 2015 GUIDE TO SUBMIT TING AND REPORTING PQRS IN 2015 THROUGH TRAKNET
PQRS in TRAKnet 2015 GUIDE TO SUBMITTING AND REPORTING PQRS IN 2015 THROUGH TRAKNET What is PQRS? PQRS is a quality reporting program that uses negative payment adjustments to promote reporting of quality
More informationChapter 3 - Does Low Well-being Modify the Effects of
Chapter 3 - Does Low Well-being Modify the Effects of PRISMA (Dutch DESMOND), a Structured Selfmanagement-education Program for People with Type 2 Diabetes? Published as: van Vugt M, de Wit M, Bader S,
More informationTitle: DreamTel; Diabetes Risk Evaluation and Management Tele-monitoring Study
Author's response to reviews Title: DreamTel; Diabetes Risk Evaluation and Management Tele-monitoring Study Authors: Sheldon Tobe (sheldon.tobe@sunnybrook.ca) Joan Wentworth (jwentworth@miwayawinhealth.org)
More information2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals
Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals Sudden and unexpected deaths in an adult population, Cape Town, South Africa, 2001-2005 1 Sudden and unexpected
More informationNOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada
September 24, 2007 NOTICE Our file number: 07-122151-509 Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada The final version of the Health Canada guidance
More informationONE of every seven dollars spent on health care in the
0021-972X/98/$03.00/0 Vol. 83, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Clinical and Economic Impact of Implementing a Comprehensive
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More information2014 ACO GPRO Audit What this means for your practice. Sheree M. Arnold ACO Clinical Transformation Specialist
2014 ACO GPRO Audit What this means for your practice Sheree M. Arnold ACO Clinical Transformation Specialist Agenda Catholic Medical Partners ACO overview Attribution and sampling of patients ACO quality
More information